SAUDI-ECONOMY-PLANNING
19.1.2024 08:10:31 CET | Business Wire | Press release
Saudi Arabia is prioritizing peace and prosperity in its efforts to lead the Middle East towards stability and security amid ongoing geopolitical volatility in the region, the World Economic Forum (WEF) Annual Meeting 2024 heard today from Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240118880673/en/
Saudi Ambassador to US says Kingdom prioritizing ‘peace and prosperity’ policies at the World Economic Forum 2024 (Photo: AETOSWire)
“The Kingdom has not put normalization at the heart of its policy. It’s put peace and prosperity at the heart of its policy,” she said in a session on ‘Saudi Arabia: The Course Ahead’.
HRH Princess Reema emphasized Saudi Arabia’s focus on the “Palestinian people who deserve a state, sovereignty, and a pathway that is irrevocable. That is how we get security. We carry peace, we carry prosperity, we carry safety, and we deliver it through the Palestinian statehood.”
In the same session, His Excellency Adel A. Aljubeir, Saudi Arabia’s Minister of State for Foreign Affairs, Member of the Council of Ministers and Envoy for Climate, spoke of the need to address climate change scientifically, decoupled from emotions and hypocrisy.
“The world’s appetite for energy is unlimited. The additional increase of energy supplies has to come from non-oil resources,” Aljubeir said, noting that, “We are saying we have a problem, and the problem has to do with climate change. And we need to tackle this problem in a serious, scientific manner. We need to deal with it without emotions, we need to deal with it without trying to score political points.”
His Excellency Mohammed Aljadaan, Saudi Arabia’s Minister of Finance, emphasized that the Kingdom is determined to double down on what it is doing on its economy because the region and the world need a strong Saudi.
Aljadaan highlighted that the Kingdom’s non-oil GDP is growing, unemployment is at the lowest level, and women's participation in the workforce has already surpassed the target set under the Saudi Vision 2030.
In an earlier session on ‘MENA’s Economic Dilemma: Reforms Amid Uncertainty’, His Excellency Faisal F. Alibrahim, Saudi Arabia’s Minister of Economy and Planning, described the resilient nature of the region. He said the Middle East “always comes out of challenges as a better version of itself” adding that it has an opportunity to “co-author the future of the global economy”.
Alibrahim touched on national transformations, highlighting the importance of delivering “consistently with a boldness and a view to collaborate with the world. Vision 2030 is an evolution, a transformation that is taking us to where we want to be as an economy and society.”
In the morning, a session on ‘Ocean Regeneration Through Collaborative Innovation’ explored approaches and solutions to environmental challenges.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118880673/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
